Journal of Clinical Oncology · 2003 · 170 citations · 6 references
MedicineBiostatisticsOncologyCancer EpidemiologyEpidemiologic MethodsSurvival AnalysisCancer Survival AnalysisKaplan-meier EstimationLife ExpectancyLung CancerPrognostic AssessmentSurvival ModelingAge-specific SurvivalConditional Survival ModelsKaplan-meier Confidence IntervalsKaplan-meier Survival EstimatesPrognostic Factors AnalysisSurvival ProbabilitySurvival Probability EstimationSurvival Rates
PURPOSE: The survival probability of patients with lung cancer is usually based on the extent of disease as assessed at the time of diagnosis. The discouraging 5-year survival is often reported (< 10%) without taking into account changes in the survival probability as time advances from diagnosis. PATIENTS AND METHODS: Conditional survival estimates by sex, age, extent of disease, and histology were estimated for patients diagnosed with lung cancer in Denmark from 1943 to 1997. Survival probabilities were calculated by the Kaplan-Meier method, and cumulative survival estimates were used to derive conditional survival estimates. RESULTS: For every additional year survived, the probability of surviving the next 5 years increases from 33% (men) and 36% (women) after the first year, to 60% (men) and 67% (women) who have survived 5 years. The 5-year survival probability of patients younger than 49 years who had survived the first year was 33%, and increased to 81% after the fifth year. Corresponding estimates for 60- to 69-year-old patients were 23% and 52%. The conditional survival differed greatly among patients with localized and regional disease (29% and 10%, respectively) in the first year, but converged with time (52% and 47%, respectively) after 5 years. The conditional survival is similar in patients with squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma, but is markedly lower in patients with small-cell carcinoma. CONCLUSION: For patients who have survived more than 1 year, the conditional survival probability provides a more accurate estimate of survival as compared with the conventional observed survival rates.
6
Molecular and cellular aspects of the secretory immunoglobulin system*
Per Brandtzaeg · Apmis · 1995 · 264 citations
Variation in survival of patients with lung cancer in Europe, 1985–1989
M.L.G. Janssen‐Heijnen, Gemma Gatta, D Forman et al. · European Journal of Cancer · 1998 · 142 citations
Conditional median survival of patients with advanced carcinoma
Ikuko Kato, Richard K. Severson, Ann G. Schwartz · Cancer · 2001 · 85 citations · Full text
Medicine, Biostatistics, Oncology +17
Anders Engeland, Tor Haldorsen, Steinar Tretli et al. · PubMed · 1995 · 78 citations
Medicine, Biostatistics, Oncology +17